These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37166199)

  • 41. Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant.
    Mao J; McPheeters JT; Zhang D; Acosta CJ; Finelli L
    Curr Med Res Opin; 2018 Apr; 34(4):741-749. PubMed ID: 28945107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study.
    Tsai TF; Yao CA; Yu HS; Lan CC; Chao SC; Yang JH; Yang KC; Chen CY; White RR; Psaradellis E; Rampakakis E; Kawai K; Acosta CJ; Sampalis JS
    Int J Dermatol; 2015; 54(5):529-36. PubMed ID: 25209019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
    Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
    J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
    Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
    N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live.
    Bruxvoort KJ; Liang AS; Harpaz R; Qian L; Sy LS; LaRussa P; Schmid DS; Luo Y; Takhar H; Tseng HF
    Vaccine; 2019 Jun; 37(26):3478-3484. PubMed ID: 31088744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
    Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?
    Duracinsky M; Paccalin M; Gavazzi G; El Kebir S; Gaillat J; Strady C; Bouhassira D; Chassany O
    BMC Infect Dis; 2014 Oct; 14():529. PubMed ID: 25273329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
    Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
    J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy.
    Matthews S; De Maria A; Passamonti M; Ristori G; Loiacono I; Puggina A; Curran D
    Open Forum Infect Dis; 2019 Feb; 6(2):ofz007. PubMed ID: 30793003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
    Boutry C; Hastie A; Diez-Domingo J; Tinoco JC; Yu CJ; Andrews C; Beytout J; Caso C; Cheng HS; Cheong HJ; Choo EJ; Curiac D; Di Paolo E; Dionne M; Eckermann T; Esen M; Ferguson M; Ghesquiere W; Hwang SJ; Avelino-Silva TJ; Kosina P; Liu CS; Markkula J; Moeckesch B; Murta de Oliveira C; Park DW; Pauksens K; Pirrotta P; Plassmann G; Pretswell C; Rombo L; Salaun B; Sanmartin Berglund J; Schenkenberger I; Schwarz T; Shi M; Ukkonen B; Zahaf T; Zerbini C; Schuind A; Cunningham AL;
    Clin Infect Dis; 2022 Apr; 74(8):1459-1467. PubMed ID: 34283213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain?
    Harbecke R; Jensen NJ; Depledge DP; Johnson GR; Ashbaugh ME; Schmid DS; Breuer J; Levin MJ; Oxman MN
    Vaccine; 2020 Jan; 38(2):150-157. PubMed ID: 31679866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study.
    Pickering G; Gavazzi G; Gaillat J; Paccalin M; Bloch K; Bouhassira D
    BMJ Open; 2016 Feb; 6(2):e009689. PubMed ID: 26892790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genital Herpes Zoster as Possible Indicator of HIV Infection.
    Ljubojević Hadžavdić S; Kovačević M; Skerlev M; Zekan Š
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):337-338. PubMed ID: 30665486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [How I prevent...herpes zoster by vaccination].
    Nikkels AF; Piérard GE
    Rev Med Liege; 2007 Jan; 62(1):44-7. PubMed ID: 17343129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice.
    Bouhassira D; Chassany O; Gaillat J; Hanslik T; Launay O; Mann C; Rabaud C; Rogeaux O; Strady C
    Pain; 2012 Feb; 153(2):342-349. PubMed ID: 22138256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Herpes Zoster Vaccine].
    Watanabe D
    Uirusu; 2018; 68(1):21-30. PubMed ID: 31105132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
    Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
    Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
    Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.